US FDA sets October date for review of Medtronic's Endeavor stent:
This article was originally published in Clinica
Executive Summary
A US FDA advisory panel is to review the premarket approval (PMA) application for Medtronic's Endeavor drug-eluting stent (DES) next month, the Minneapolis, Minnesota company revealed yesterday. The agency's Circulatory System Devices Panel is scheduled to meet on October 10-11, with Endeavor the only DES on the agenda for review during the meeting.